nearmejobs.eu
We are looking for 10 highly motivated PhD candidates to fill positions across 7 top European research centres/medical university hospitals.
The largest challenge associated with leukemia treatment is persistence of residual therapy-resistant cancer cells, called minimal residual disease (MRD), which underlies disease relapse and is responsible for the low survival rates of patients. Currently, knowledge on mechanisms of persistence of MRD and initiation of leukemia relapse is lacking, making development of therapeutics eradicating MRD difficult and hampering improvement of patient cure rates. The MIRACLE network will take an integrated, multidisciplinary and intersectoral approach to address the key unresolved questions on the molecular and cellular basis of acute leukemia MRD.
MIRACLE is a Marie Skłodowska-Curie doctoral network aiming to educate a new generation of researchers optimally equipped to advance and accelerate development of novel therapeutics directed to leukemia MRD, and to progress effective treatments to the clinic. MIRACLE will elucidate the leukemia MRD landscape by integrating the knowledge on mechanisms driving persistence of MRD from different angles, and by the subsequent design of efficient and less toxic, novel targeted combination therapy with increased capacity to induce deep responses in patients.
The project is an international, multidisciplinary and multisectoral training program consisting of 23 academic and non-academic partners from 8 EU countries (The Netherlands, Belgium, Germany, France, Spain, Italy, Czech Republic, United Kingdom). MIRACLE aims to train 10 doctoral candidates to become the next generation of entrepreneurial researchers with leading positions in academia and industry. The researchers will be trained to obtain a unique combination of skills in innovative high-tech technologies, advanced data analysis tools and artificial intelligence, organ-on-chip MRD models, and drug and immunotherapy testing, and will come up with innovative ideas to advance future leukemia treatment by integration of several disciplines and data sources. The MIRACLE joint programme will consist of an individual research project and a comprehensive training program including international mobility and intersectoral secondments.
MIRACLE-Leukemia is a European project funded by the European Union’s Horizon Europe’s Research and Innovation Program under the Marie Sklodowska-Curie Actions Grant Agreement nr. 101167512.
_____________
What we are looking for:
10 highly motivated PhD candidates to fill positions across our European research centres/medical university hospitals located in 7 EU countries.
_____________
Skills/Qualifications needed:
_____________
What we offer:
_____________
The 10 PhD candidates are recruited for the following research projects:
Visit our MIRACLE-Leukemia website to find the 10 Research project descriptions, host organization, supervisor and work location.
_____________
Applicationn and selection process:
You can apply for these jobs no later than February 15st. It is very important to make use you match our requirements. In addition we only accept applications who make use the MIRACLE application form. The application form and requested document need to merged into 1 PDF file.
Important notes:
MIRACLE-Leukemia is a Marie Skłodowska-Curie doctoral network and will address one of the greatest challenges in leukemia treatment; the persistence of therapy-resistant cancer cells, known as minimal residual disease (MRD). The Doctoral Network of 10 PhD students will tackle the problem of MRD in an integrated collaborative effort to prevent MRD-induced leukemia relapses and to drastically increase survival chances of leukemia patients. The project, funded by the EU Horizon Europe programme, is coordinated by the Amsterdam UMC department of Hematology.
Despite advancements in cancer research, a lack of understanding of the mechanisms behind MRD persistence and relapse has hindered progress in developing effective therapies. Adding to this challenge is the fragmented expertise on MRD across Europe and a lack of multidisciplinary scientists capable of integrating insights from transcriptomics, epigenetics, metabolism, and immunology. Moreover, there has been thus far no dedicated doctoral training program tackling the problem of leukemia MRD.
By employing 10 highly talented doctoral candidates, the MIRACLE-Leukemia consortium aims to execute cutting-edge studies in several academic and industrial institutes while training the PhD students in multidisciplinary and transferable skills. The 10 researchers will work on individual research projects and benefit from a comprehensive program that contains scientific, technical, and entrepreneurial training. MIRACLE-Leukemia will not only generate impactful research but also actively contribute to Europe’s Mission Cancer goal of increasing cure rates and improving the lives of cancer patients. The project aims to raise public awareness, influence policy, and create a lasting legacy in leukemia treatment.
MIRACLE is an international, multidisciplinary and multisectoral training program consisting of 23 academic and non-academic partners from 8 EU countries (The Netherlands, Belgium, Germany, France, Spain, Italy, Czech Republic, United Kingdom).
The 10 research projects collectively focus on advancing the understanding and treatment of acute leukemia MRD by leveraging cutting-edge techniques such as artificial intelligence, single-cell omics, multiomic and metabolomic profiling, identification of niche-dependent MRD vulnerabilities, in vivo CRISPR-CAS9 screening and epigenetic single cells analysis. The studies aim to optimize treatment decisions, develop translational organ-on-chip 3D MRD models, and design immune-based therapeutic approaches such as CAR T cells homing to the bone marrow and directed to therapy-induced senescence, persistent leukemic blasts in Down syndrome patients, acute leukemia MRD and leukemic stem cells (LSCs). Together, the 10 researchers will address the key unresolved questions on the molecular and cellular basis of acute leukemia MRD and bridge preclinical and clinical research to come up with novel ideas on how to eradicate MRD and improve patient outcomes.
Boelelaan 1117
Amsterdam
Zuid Holland
1081 HV
Netherlands
Apply now
To help us track our recruitment effort, please indicate in your email – cover/motivation letter where (nearmejobs.eu) you saw this job posting.
Job title: Postdoctoral Research Fellow Company University of Edinburgh Job description Job Description: UE07: £40,247…
Job title: Manager Human Resources Canada Company Advantage Solutions Job description , Customer Service) Summary…
Job title: Key Account Manager - Apparel Company Avery Dennison Job description industries worldwide —…
Job title: Working Aviation Supervisor - Night Shift Company Foxtrot Aviation Services Job description FoxTrot…
Job title: Operational Purchaser Company Hitachi Energy Job description or drive development of our internal…
Job title: Senior Project Manager (Maritime) Company KBR Job description Title: Senior Project Manager (Maritime)…
This website uses cookies.